Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adlai Nortye (ANL) Goodwill & Intangibles (2022 - 2025)

Adlai Nortye (ANL) reported Goodwill & Intangibles of $19000.0 for Q4 2025, down 52.5% year-over-year from $40000.0 in Q4 2024, and down 34.48% on a QoQ basis from $29000.0 in Q2 2025.

Adlai Nortye (ANL) has 4 years of Goodwill & Intangibles data on file, last reported at $19000.0 in Q4 2025.

  • Quarterly Goodwill & Intangibles fell 52.5% year-over-year to $19000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19000.0 (down 52.5% YoY) and the FY2025 annual result came in at $19000.0, down 52.5% from the prior year.
  • Goodwill & Intangibles slipped to $19000.0 in Q4 2025 per ANL's latest filing, from $29000.0 in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $89000.0 in Q4 2022 and bottomed at $19000.0 in Q4 2025.
  • The 4-year median for Goodwill & Intangibles is $45500.0 (2024), against an average of $48500.0.
  • The widest annual swing landed in 2023, when Goodwill & Intangibles retreated 29.21%; it then tumbled 52.5% in 2025.
  • Tracing ANL's Goodwill & Intangibles over 4 years: stood at $89000.0 in 2022, then declined by 29.21% to $63000.0 in 2023, then slumped by 36.51% to $40000.0 in 2024, then plunged by 52.5% to $19000.0 in 2025.
  • Per Business Quant, the three latest ANL Goodwill & Intangibles figures stand at $19000.0 (Q4 2025), $29000.0 (Q2 2025), and $40000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Adlai Nortye 23,840.00 -8.03 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 19,000.00
Jun 30, 2025 29,000.00
Dec 31, 2024 40,000.00
Jun 30, 2024 51,000.00
Dec 31, 2023 63,000.00
Dec 31, 2022 89,000.00